BlossomHill Therapeutics, Inc.

BLSM chart

BlossomHill Therapeutics, Inc. news

• BlossomHill at Guggenheim: a macrocyclic push in cancer drugs By Investing.com

  Investing.com India · Nov 10, 3:50 PM EST

• BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC

  Yahoo Finance · Nov 9, 7:00 AM EST

• BlossomHill Therapeutics, Inc. (BLSM) stock price, news, quote and history

  Yahoo Finance Australia · Nov 4, 3:29 PM EST

• BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting

  Yahoo Finance · Nov 4, 7:00 AM EST

• BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference

  Yahoo Finance · Nov 3, 7:00 AM EST

• BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer

  Yahoo Finance · Oct 22, 7:00 AM EDT

• BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

  Yahoo Finance · Sep 28, 7:00 AM EDT

• BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

  Yahoo Finance · Sep 18, 7:00 AM EDT

• BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update

  investorshub.advfn.com · Sep 15, 10:13 AM EDT

• BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

  Yahoo Finance · Sep 15, 7:00 AM EDT

• BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

  Yahoo Finance · Sep 3, 7:00 AM EDT

• BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

  Yahoo Finance · Sep 1, 7:00 AM EDT

BlossomHill Therapeutics, Inc. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 10-Q10-Q2026-09-18
• 8-K8-K2026-09-18
• 8-K8-K2026-09-15
• 8-K8-K2026-08-10
• S-1S-12026-07-17

About BlossomHill Therapeutics, Inc.

Ticker

BLSM (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

San Diego, CA

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

1839970

Frequently asked questions